McKesson lifts fiscal EPS guidance; Wellverse sales rise, profit falls
McKesson raised fiscal EPS guidance to $44.20–$45.00. Wellverse Medical-Surgical posted ~4% sales growth but ~20% drop in adjusted operating profit, and the company plans an IPO in H2 2027 for Wellverse.
00, implying about 13—15% reported growth and 15—17% adjusted growth. Wellverse Medical-Surgical posted about 4% sales growth, but adjusted operating profit fell about 20% due to mix and one-time costs, with an IPO planned for H2 2027.